Selective Alopecia with Mitoxantrone

Publisher Website
Google Scholar
Abstract
To the Editor: The ongoing examination of new drugs for the treatment of malignant disorders is a consequence of the need to develop more effective as well as less toxic therapy. One of the new drugs currently under investigation is the anthracenedione mitoxantrone. Recent studies have shown that it is effective in breast cancer,1 lymphoma,2 and leukemia.3 The drug may be less cardiotoxic than conventional anthracyclines4 and may also be less likely to induce nausea, vomiting, or stomatitis. Hair loss is less commonly seen than with doxorubicin, and this makes the drug more acceptable for patients who are worried about . . .

This publication has 2 references indexed in Scilit: